Development and Validation of a Practical Two-Step Prediction Model and Clinical Risk Score for Post-Thrombotic Syndrome

Citation for published version (APA):

Amin, E. E., van Kuijk, S. M. J., Joore, M. A., Prandoni, P., ten Cate, H., & ten Cate-Hoek, A. J. (2018). Development and Validation of a Practical Two-Step Prediction Model and Clinical Risk Score for Post-Thrombotic Syndrome. *Thrombosis and Haemostasis*, 118(7), 1242-1249. <https://doi.org/10.1055/s-0038-1655743>

Document status and date:

Published: 01/07/2018

DOI:

[10.1055/s-0038-1655743](https://doi.org/10.1055/s-0038-1655743)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Development and Validation of a Practical Two-Step Prediction Model and Clinical Risk Score for Post-Thrombotic Syndrome

Elham E. Amin^{1,2} Sander M. J. van Kuijk² Manuela A. Joore² Paolo Prandoni³ Hugo ten Cate^{1,4}
Arina J. ten Cate-Hoek^{1,4}

¹Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands

²Department of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands

³Arianna Foundation on Anticoagulation, Bologna, Italy

⁴Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands

Address for correspondence Elham E. Amin, MD, P.O. Box 616, 6200 MD, Maastricht, The Netherlands
(e-mail: e.amin@maastrichtuniversity.nl).

Thromb Haemost 2018;118:1242–1249.

Abstract

Background Post-thrombotic syndrome (PTS) is a common chronic consequence of deep vein thrombosis that affects the quality of life and is associated with substantial costs. In clinical practice, it is not possible to predict the individual patient risk. We develop and validate a practical two-step prediction tool for PTS in the acute and sub-acute phase of deep vein thrombosis.

Methods Multivariable regression modelling with data from two prospective cohorts in which 479 (derivation) and 1,107 (validation) consecutive patients with objectively confirmed deep vein thrombosis of the leg, from thrombosis outpatient clinic of Maastricht University Medical Centre, the Netherlands (derivation) and Padua University hospital in Italy (validation), were included. PTS was defined as a Villalta score of ≥ 5 at least 6 months after acute thrombosis.

Results Variables in the baseline model in the acute phase were: age, body mass index, sex, varicose veins, history of venous thrombosis, smoking status, provoked thrombosis and thrombus location. For the secondary model, the additional variable was residual vein obstruction. Optimism-corrected area under the receiver operating characteristic curves (AUCs) were 0.71 for the baseline model and 0.60 for the secondary model. Calibration plots showed well-calibrated predictions. External validation of the derived clinical risk scores was successful: AUC, 0.66 (95% confidence interval [CI], 0.63–0.70) and 0.64 (95% CI, 0.60–0.69).

Conclusion Individual risk for PTS in the acute phase of deep vein thrombosis can be predicted based on readily accessible baseline clinical and demographic characteristics. The individual risk in the sub-acute phase can be predicted with limited additional clinical characteristics.

Keywords

- post-thrombotic syndrome
- clinical risk score
- prediction model
- deep vein thrombosis
- validation

received
January 24, 2018
accepted after revision
April 12, 2018

© 2018 Georg Thieme Verlag KG
Stuttgart · New York

DOI <https://doi.org/10.1055/s-0038-1655743>.
ISSN 0340-6245.

Introduction

Post-thrombotic syndrome (PTS) is a chronic condition that develops in 25 to 50% of the patients after deep vein thrombosis (DVT) of the leg.^{1,2} It is a compilation of signs and symptoms varying from pain and oedema to venous ulcerations. The presence of (severe) PTS is associated with threefold higher medical and total costs compared with DVT in the absence of PTS.^{3,4} Moreover, quality of life declines as PTS becomes worse.^{1,2} Although the exact pathophysiology of the condition is not fully understood, several modifiable and non-modifiable risk factors have previously been identified as established or potential predictors: (ipsilateral) DVT recurrence,^{2,5} poor regulation of international normalized ratio (INR),^{6,7} proximal DVT,^{3,8,9} higher body mass index,^{8,10} presence of varicose veins,^{9,11} presence of residual vein obstruction,^{3,12} older age,^{5,9} gender,⁸ elevated levels of biomarkers such as C-reactive protein (CRP), D-dimer, factor VIII (FVIII), interleukin (IL)-6, IL8 and intercellular adhesion molecule 1 (ICAM-1),^{13–15} and type and quality of anticoagulant prescribed.^{6,7,16} Thus far, however, it is not possible in clinical practice to combine these factors and predict the risk of PTS despite the need to identify patients at high risk.

One of the most important hurdles for development of a prediction model for PTS is the absence of a gold standard for the diagnosis. The diagnosis is based on one of the several clinical scores that have been developed over the years.^{1,17–19} In 2008, the International Society for Thrombosis and Haemostasis (ISTH) Subcommittee for Standardization recommended the Villalta score as the preferred clinical score.¹⁸

In the absence of effective therapies for PTS preventive measures remain warranted. To this end, elastic compression stockings are widely applied and although the effectiveness has been disputed, a recent meta-analysis showed a 30% reduction in occurrence of PTS achieved by compression stockings.²⁰ In addition, other measures such as physical activity, lymphatic drainage, the use of venous-return assist devices and veno-active drugs that were found to enhance the efficacy of compression therapy in patients with PTS, might if initiated at an earlier point in time in selected patients, potentially prevent PTS.^{12,21–24} Moreover, in patients with highest risk of PTS catheter-directed thrombolysis might be considered.^{25,26} If the individual risk of patients is known, treatment can be personalized and hence expected to be more efficient. We therefore developed and externally validated a two-step prediction model for PTS and derived simplified clinical risk scores that could serve as a tool for identification of patients at increased risk of PTS, as well as for better targeting of therapy. Additionally, we externally validated the clinical risk scores.

Methods

Derivation Cohort

For the development of the two-step prediction model, data from a prospective DVT cohort were used. Data were collected from June 2003 until June 2013. This cohort was part

of medical care evaluation in a clinical care pathway within the Maastricht University Medical Center+ in the Netherlands (medical ethical approval registration number 15–4–256) and was comprised of adult patients who were followed up for 2 years after DVT had been objectively confirmed. There were no exclusion criteria. A medical doctor assessed the signs and symptoms of PTS using the Villalta score at 3, 6, 12 and 24 months post-DVT. Baseline measurements (first office visit within 2–3 weeks following acute presentation and treatment for thrombosis) included: height, weight, medical history, current health status, presence of venous insufficiency, hypertension, smoking status, family history for thrombosis and appraisal of the triggering factors for DVT such as immobilization, surgery, oral contraceptive use or presence of malignancy. Follow-up measurements included: assessment of residual vein obstruction when discontinuation of anticoagulation was considered, and plasma levels of D-dimer, levels of FVIII and CRP. All patients received anticoagulation treatment for a minimum of 3 months and compression therapy for at least 6 months.

Sample Size

The occurrence of PTS is between 20 and 50%. A conservative percentage of 35% was chosen for the sample size calculation. We followed the suggested sample size calculation for logistic regression,²⁷ where p is the smallest of the proportions of negative or positive cases in the population and k is the number of covariates (the number of independent variables), then the minimum number of cases to include is: $N = 10k/p$. We had 12 covariates to include in the model and the proportion of positive cases in the population is approximately 0.35 (35%). The minimum number of cases required is therefore $N = 10 \times 12/0.35 = 343$. This would implicate that a cohort of 343 patients is required for our 12-candidate predictors.

Outcome Measure

The outcome was PTS defined as a single Villalta score of ≥ 5 as of 6 months after diagnosis of DVT. The Villalta score is comprised of several items of leg complaints and/or objectively confirmable signs. The items include pain, cramps, heaviness, itching, tingling, oedema, redness, skin indurations, hyperpigmentation, venectasia, pain on calf compression and, in the most severe cases, venous ulcerations. Depending on the severity, each item is scored on a 4-point scale. The presence or history of a venous ulcer is scored as 33 points.²⁸

Candidate Predictors

As candidate predictors, we included predictors that are reported in the literature except for IL-6 and -8, ICAM-1 and type of anticoagulant because data on these predictors were not available from the derivation cohort. We also included type of DVT (provoked) as a candidate predictor.

Model Development

We developed a two-step model consisting of a model to be applied at baseline to predict the probability of developing

PTS at 6 months, and a model to be applied at 6 months to predict the probability of PTS 24 months after initial thrombosis for those patients who did not develop PTS till then. The first model included only baseline demographics and clinical characteristics. The second model was similar to the baseline model with the addition of the following potential predictor variables: levels of plasma biomarkers such as D-dimer, FVIII and CRP, INR regulation during the first 3 months following acute DVT and presence of residual vein obstruction. Incomplete data were completed based on medical records if possible.

Multiple imputation was used to impute the incomplete records, since using only complete records may cause a considerable loss of precision and is more likely to bias results.²⁹ Sensitivity analysis was performed to exclude significant differences between results of the imputed and the original data. Variable selection in the final models was performed using backward stepwise elimination in multivariable logistic regression analysis. A *p*-value of 0.3 was chosen for excluding variables from the model so that potentially important predictors were not erroneously deleted.³⁰

First, all analyses were performed with continuous variables as such. To develop simple and practical models, continuous variables were subsequently dichotomized based on cut-off values derived from literature or, if no information was available, based on the data. Models with and without the addition of biomarkers were assessed. The discriminative ability of the models was expressed as the magnitude of the area under the receiver operating characteristic curve (AUC). The ability of the models (baseline model and secondary model) to generate predicted probabilities comparable to observed outcome frequencies was determined by visually assessing the calibration curves. The analyses were performed using SPSS version 23. R version 3.1.3 was used to perform the internal validation of the models and to obtain calibration plots. The predictive performance of the models was explored. Based on the regression coefficients of the models a practical clinical score was estimated. These clinical scores for the baseline and secondary models were externally validated.

Internal Validation

To internally validate the two-step model, we used bootstrapping techniques.³⁰ We drew 1,000 bootstrap samples from the original dataset and re-estimated the model on each sample. The average differences in performance measures of those models on the bootstrap sample and the original data are estimators of optimism in the model performance. We subtracted the measures of optimism from the initial performance measures (i.e. AUC) to obtain optimism-corrected measures of performance. In addition, we computed a shrinkage factor. The regression coefficients were subsequently multiplied by this shrinkage factor. These shrunk coefficients combined with a re-estimated intercept render future predictions less extreme, and counteract the effect of over-fitting a prediction model. The individual probability estimation for patients can be performed using the following equation: $\text{Probability} = 1/(1 + \exp(-LP))$, in which LP is the

linear combination of the intercept and all coefficients multiplied by their respective patient values.

External Validation

The validation cohort consisted of 1,107 adult patients from Padua University Hospital outpatient clinic in Italy who were diagnosed with proximal DVT of the leg. Exclusion criteria were: history of ipsilateral DVT less than 2 years ago, thrombectomy, arterial thrombotic events, active cancers, deficiencies in natural anticoagulants or medical conditions leading to prolonged immobilization. All patients received anticoagulation. The duration of anticoagulation depended on international guidelines, patients' preferences and risk profile. All patients received compression therapy for at least 6 months. PTS was assessed at 3, 6, 12, 18 and 24 months after DVT diagnosis. Three months after DVT compression, ultrasonography was performed to determine the presence of residual thrombosis. All variables of the original model except for smoking status were present in the validation cohort. There were no missing values for the available variables. Model performance was quantified as the AUC. Because we validated clinical risk scores derived from the prediction models, calibration would not have additional value as the resulting scores do not reflect probabilities. External validation was performed with SPSS version 23.

Reporting

This study adhered to the Transparent Reporting of a multi-variable prediction model for Individual Prognosis or Diagnosis (TRIPOD) (► **Supplementary Material**, available in the online version) statement for reporting.³¹

Results

The derivation cohort consisted of 479 patients of whom 28 were eventually excluded from the analysis due to large amount of missing information on follow-up visits. All 1,107 patients in the validation cohort were included in the analyses. ► **Table 1** shows the baseline demographic and clinical characteristics of both study populations.

In the derivation cohort, at 6 months after DVT 22.8% developed PTS. Of the remaining patients who did not develop PTS until 6 months post-DVT, 29.6% developed PTS in the 18 months following the initial period of 6 months. At the end of the 24 months' follow-up, 45.7% of the entire cohort was diagnosed with PTS.

Model Development

► **Table 2** illustrates the final reduced prediction models with the dichotomized predictors based on backward elimination, before and after internal validation. The bootstrapping procedure yielded shrinkage factors between 0.81 and 0.86.

Model Performance

The discriminative ability of the models is represented as the AUC. The AUCs for the baseline model followed by

Table 1 Baseline and clinical characteristics of the study populations

	Derivation cohort N = 451	Validation cohort N = 1,107
Characteristic		
Age > 56, n (%)	239 (53.0)	726 (65.6)
Male sex, n (%)	228 (50.6)	545 (49.2)
Smoker, n (%)	103 (22.8)	Unknown
Varicose veins, n (%)	67 (14.9)	355 (32.1)
Body mass index > 30, n (%)	132 (29.3)	127 (11.5)
Previous deep vein thrombosis, n (%)	91 (20.2)	164 (14.8)
Provoked thrombosis, n (%)	242 (53.7)	526 (47.5)
Iliofemoral thrombosis, n (%)	220 (48.8)	585 (52.8)

the secondary model were 0.71 and 0.60 after internal validation. Sensitivity analysis showed no difference in model performance between using only complete cases and the imputed data.

The differences between the baseline models based on continuous and dichotomized variables were negligible. For the secondary model the differences were also small, the highest values of AUC (0.67, 95% confidence interval [CI], 0.61–0.73) was reached for the model with continuous variables and containing all biomarkers. The calibration plots are presented in ►Fig. 1. Visual inspection shows that the calibration plots closely follow the 45° degree line thereby indicating good calibration. ►Table 3 shows model characteristics for several cut-off values of predictive probabilities for PTS. Efficiency of the models can be read from the table by dividing the denominator found in the column *N* under negative predictive value, by *N* for the corresponding model. For example, at a threshold of 15%, 146 out of 451 (32.4%) are allocated to a low risk for PTS and might be excluded from extra interventions, at the cost of 9.9% missed PTS.

►Table 4 presents the simplified clinical risk scores for the baseline and secondary model with PTS. A score of ≤ 2 points is associated with a 10% risk for the development of PTS, a score of 3 or 4 points indicates a risk of 20% and a score of ≥ 5 points is associated with a risk of 40%. The AUC of the models with the clinical risk scores equalled 0.73 (95% CI, 0.67–0.78) for the baseline model and 0.62 (95% CI, 0.55–0.68) for the secondary model.

External Validation

The occurrence of PTS at 6 months in the validation cohort was 20.6% and in the following 18 months another 22.4% of

Table 2 Prediction model for post-thrombotic syndrome

	Initial model		Internally validated model
Variable	Regression coefficient	OR (95% CI)	Regression coefficient ^a
Baseline model			
Intercept	–2.593	–	–2.428
Age > 56	0.779	2.18 (1.30–3.66)	0.694
Body mass index > 30	0.801	2.22 (1.36–3.66)	0.713
Varicose veins	1.505	4.50 (2.51–8.08)	1.339
Smoking	0.551	1.74 (1.01–3.03)	0.490
History of DVT	0.573	1.77 (1.01–3.11)	0.510
Male sex	–0.429	0.65 (0.39–1.08)	–0.382
Iliofemoral thrombosis	0.556	1.74 (0.99–3.06)	0.495
Provoked DVT	0.345	1.41 (0.84–2.37)	0.307
Secondary model			
Intercept	–1.521	–	–1.393
Age > 56	0.369	1.45 (0.89–2.35)	0.299
Body mass index > 30	0.391	1.48 (0.87–2.53)	0.317
Varicose veins	1.032	2.81 (1.36–5.80)	0.836
Smoking	0.477	1.61 (0.91–2.84)	0.387
Residual vein obstruction	0.342	1.41 (0.86–2.31)	0.277
History of DVT			–
Male sex	–	–	–
Iliofemoral thrombosis	–	–	–
Provoked DVT	–	–	–

Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; OR, odds ratio.

^aMultiplied by shrinkage factor (0.86 for the baseline and 0.81 for the second model) to adjust for over-fitting.

the remaining patients developed PTS. Validation of the simplified clinical risk scores without one predictor (smoking status) showed an AUC of 0.66 (95% CI, 0.63–0.70) for the baseline model and 0.64 (95% CI, 0.60–0.69) for the secondary model.

Fig. 1 The calibration plots of the baseline model (A) and the secondary model (B) for post-thrombotic syndrome.

Discussion

We developed a baseline prediction model (clinical risk score) for PTS that is practical and easy to use. The model has good predictive performance with an AUC of 0.71 and an AUC of 0.73 for the derived risk score. Risk assessment can be performed in the acute phase as soon as the patient is diagnosed with DVT, and is based on only those variables that are readily available at baseline. The secondary model and clinical risk score can subsequently be applied in the sub-acute phase (6 months after venous thrombosis) and could be used to identify those patients that may either stop preventive therapy or are in need of continued or adjunctive therapy. The secondary prediction model discriminates moderately between patients at high risk and low risk for PTS with AUCs of 0.60 (AUC clinical risk score, 0.62). The addition of biomarkers did not improve the models' discriminative ability and had overall very little influence on the results. This might be due to the fact that the biomarkers available from the derivation cohort were measured in the chronic phase of DVT. It could therefore very well be that biomarkers measured in the acute phase of DVT may have additional predictive value and might thereby improve the models' performance.³²

The efficiency of the models was the greatest for the baseline model at a threshold of 15% in which 32.4% of patients are classified as low risk at the cost of 9.9% missed cases. In previously published studies, margins set even as high as 10% were deemed acceptable.³³ It needs, however, to be determined which threshold is more desirable both from a medical perspective (accurate identification of patients at risk for PTS) and which is more desirable from a societal perspective (most efficient selection of patients that can be excluded from further treatment). It would require decision analytical modelling to

compare the savings associated with the treatment of fewer patients, to the health benefits forgone associated with the percentage of patient that was erroneously left untreated.

Validation of the baseline and secondary clinical risk scores in a new large set of patients in which the predictor smoking status was absent, showed to be successful. The baseline risk score corresponded to an AUC of 0.66 and the secondary risk score showed an AUC of 0.64, which was slightly better than in the derivation cohort. This indicates that the risk scores could also be applied to other patient populations with thrombosis. To our knowledge no externally validated prediction models for PTS exist so far, therefore comparison is not possible. At the end of November 2017, one study on the development of a prediction model for PTS has been published.³⁴ The study used data from a randomized controlled trial that compared the effect of elastic compression stockings to placebo stockings for prevention of PTS in patients with proximal DVT. Because the prediction model was developed in a trial with several inclusion and exclusion criteria, and the diagnosis of PTS was based on the Ginsberg criteria rather than the current consensus-supported Villalta score, it is not likely that the model could be readily applied to all patients with DVT. Moreover, this prediction model has not yet been externally validated. Consequently, it is not directly suitable for clinical use.

The most important limitation for the development of the models was the lack of gold standard for PTS. Another limitation is that biomarkers were measured at a later stage after DVT and that no biomarkers were available for the acute phase of DVT. Inflammatory markers in the acute phase might have offered better predictive value for PTS and thereby have increased the discriminative ability of our models. The strength of our models and

Table 3 Model characteristics

Threshold								
	Sensitivity		Specificity		Positive predictive value		Negative predictive value	
	N	%	N	%	N	%	N	%
Baseline model (N = 451)								
2.5	103/103	100	–	–	103/451	22.8	–	–
5	103/103	100	9/348	2.6	103/442	23.3	9/9	100
7.5	103/103	100	25/348	7.2	103/426	24.2	25/25	100
10	91/103	88.3	106/348	30.5	91/333	27.3	106/118	89.8
12.5	90/103	87.4	121/348	34.8	90/317	28.4	121/134	90.3
15	87/103	84.5	146/348	42.0	87/289	30.1	146/162	90.1
17.5	78/103	75.7	191/348	54.9	78/235	33.2	191/216	88.4
20	73/103	70.9	231/348	66.4	73/190	38.4	231/261	88.5
22.5	70/103	68.0	249/348	71.6	70/169	41.4	249/282	88.3
25	63/103	61.2	260/348	74.7	63/151	41.7	260/300	86.7
Secondary model (N = 301)								
2.5	103/103	100	–	–	103/348	29.6	–	–
5	103/103	100	–	–	103/348	29.6	–	–
7.5	103/103	100	–	–	103/348	29.6	–	–
10	103/103	100	–	–	103/348	29.6	–	–
12.5	103/103	100	–	–	103/348	29.6	–	–
15	103/103	100	–	–	103/348	29.6	–	–
17.5	103/103	100	–	–	103/348	29.6	–	–
20	97/103	94.2	44/245	18.0	97/298	32.6	44/50	88.0
22.5	97/103	94.2	44/245	18.0	97/298	32.6	44/50	88.0
25	70/103	68.0	124/245	50.6	70/191	36.6	124/157	79.0

Table 4 Clinical risk scores for post-thrombotic syndrome

Variable	Baseline risk assessment	Risk assessment in the sub-acute phase ^a
Age > 56	2	1
Body mass index > 30	2	1
Varicose veins	4	3
Smoking	1	1
Residual vein obstruction	–	1
Female sex	1	–
Provoked deep vein thrombosis	1	–
Iliofemoral thrombosis	1	–
History of deep vein thrombosis	1	–

Note: Risk of post-thrombotic syndrome development: Baseline model: Score 0–2 points, 10%; 3–4 points, 20%; ≥ 5 points, 40%. Secondary model: Score 0–2 points, 25%; 3–4 points, 45%; ≥ 5 points 60%.

^aSub-acute phase = 6 months after diagnosis of deep vein thrombosis.

clinical risk scores is that they are derived from a cohort of patients with DVT in which all consecutive patients were included; this will likely increase the generalizability of the models as was shown in the external validation phase. Another strength is the simplicity of the models/risk scores. The application of the baseline model is anticipated to be easy because the predictors are dichotomized and are commonly available at baseline, so this model can be used at no additional costs since no expensive diagnostic measurements are required. Even for the secondary model costs are expected to be moderate, as only the additional assessment of residual vein obstruction is needed.

Our two-step model has the potential to both improve patient care and at the same time reduce costs. At time of DVT diagnosis, based on readily accessible baseline clinical characteristics, clinicians can predict the individual patients' risk for developing PTS at 6 months after DVT. In the sub-acute phase, the individual risk can be estimated with the additional assessment of residual thrombosis. Therapy can thus be allocated to those who will likely benefit the most, which could also result in a better cost-effectiveness balance.

What is known about this topic?

- Post-thrombotic syndrome is a common chronic consequence of deep vein thrombosis that affects the quality of life to great extent and is associated with substantial costs.
- Thus far in the clinic, it is not possible to predict the individual risk of post-thrombotic syndrome in patients with deep vein thrombosis.

What does this paper add?

- A newly developed and externally validated easily applicable two-step prediction model and its corresponding risk score, could serve as a tool for identifying patients at risk of post-thrombotic syndrome.
- Consequently, preventive therapy in the acute and sub-acute phase of deep vein thrombosis can be individually tailored.

Ethical Approval

For this study, no separate ethical approval was needed or acquired, but data from the clinical care pathway in MUMC+ was used. For data collection in this pathway, approval was obtained by Maastricht University Medical Centre Ethics Committee (reference METC 15–4–256). No informed consent from participants was required.

Funding

None.

Conflict of Interest

None.

References

- Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. *Lancet* 1997;349(9054):759–762
- Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med* 1996; 125(01):1–7
- Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. *Ann Intern Med* 2008;149(10):698–707
- Guanella R, Ducruet T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. *J Thromb Haemost* 2011;9 (12):2397–2405
- Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. *Ann Intern Med* 2004; 141(04):249–256
- van Dongen CJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. *J Thromb Haemost* 2005;3(05):939–942
- Chitsike RS, Rodger MA, Kovacs MJ, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. *J Thromb Haemost* 2012;10(10):2039–2044
- Stain M, Schönauer V, Minar E, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. *J Thromb Haemost* 2005;3(12):2671–2676
- Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. *J Thromb Haemost* 2008;6(12):2075–2081
- Agno W, Piantanida E, Dentali F, et al. Body mass index is associated with the development of the post-thrombotic syndrome. *Thromb Haemost* 2003;89(02):305–309
- Ten Cate-Hoek AJ, Ten Cate H, Tordoir J, Hamulyák K, Prins MH. Individually tailored duration of elastic compression therapy in relation to incidence of the postthrombotic syndrome. *J Vasc Surg* 2010;52(01):132–138
- Prandoni P, Frulla M, Sartor D, Concolato A, Girolami A. Vein abnormalities and the post-thrombotic syndrome. *J Thromb Haemost* 2005;3(02):401–402
- Latella J, Desmarais S, Miron MJ, et al. Relation between D-dimer level, venous valvular reflux and the development of post-thrombotic syndrome after deep vein thrombosis. *J Thromb Haemost* 2010;8(10):2169–2175
- Bouman AC, Smits JJ, Ten Cate H, Ten Cate-Hoek AJ. Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome. *J Thromb Haemost* 2012;10(08): 1532–1538
- Rabinovich A, Cohen JM, Cushman M, et al. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome. *J Thromb Haemost* 2015;13(03): 398–408
- Ziegler S, Schillinger M, Maca TH, Minar E. Post-thrombotic syndrome after primary event of deep venous thrombosis 10 to 20 years ago. *Thromb Res* 2001;101(02):23–33
- Villalta S, Bagatella P, Piccioli A, Lensing A, Prins MH, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. *Haemostasis* 1994;24(158a)
- Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;133(6 Suppl):454S–545S
- Ginsberg JS, Hirsh J, Julian J, et al. Prevention and treatment of postphlebotic syndrome: results of a 3-part study. *Arch Intern Med* 2001;161(17):2105–2109
- Appelen D, van Loo E, Prins MH, Neumann MH, Kolbach DN. Compression therapy for prevention of post-thrombotic syndrome. *Cochrane Database Syst Rev* 2017;9:CD004174
- Padberg FT Jr, Johnston MV, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. *J Vasc Surg* 2004;39(01):79–87
- O'Donnell MJ, McRae S, Kahn SR, et al. Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial. *Thromb Haemost* 2008;99(03):623–629
- Ippolito E, Belcaro G, Dugall M, et al. Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study. *Panminerva Med* 2011;53(03, Suppl 1):13–19
- Kahn SR, Shrier I, Shapiro S, et al. Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. *CMAJ* 2011;183(01):37–44
- Haig Y, Enden T, Grøtta O, et al; CaVenT Study Group. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. *Lancet Haematol* 2016;3 (02):e64–e71
- Vedantham S, Goldhaber SZ, Julian JA, et al; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. *N Engl J Med* 2017;377(23):2240–2252
- Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in

- logistic regression analysis. *J Clin Epidemiol* 1996;49(12):1373–1379
- 28 Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. *J Thromb Haemost* 2009;7(05):879–883
 - 29 van Kuijk SMJ, Viegtebauer W, Peeters LL, Smits L. Bias in regression coefficient estimates when assumptions for handling missing data are violated: a simulation study. *Epidemiol Biostat Public Health* 2016;13(01):e11598
 - 30 Steyerberg EW. *Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating*. New York: Springer-Verlag; 2009
 - 31 Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ* 2015;350:g7594
 - 32 Ten Cate-Hoek AJ, Henke PK, Wakefield TW. The post thrombotic syndrome: ignore it and it will come back to bite you. *Blood Rev* 2016;30(02):131–137
 - 33 Kahn SR, Shapiro S, Wells PS, et al; SOX trial investigators. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2014;383(9920):880–888
 - 34 Rabinovich A, Ducruet T, Kahn SR. Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis. *J Thromb Haemost* 2018;16(02):262–270